Refeyn Announces SamuxMP for AAV Characterization

In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter, February 2022, Volume 17, Issue 2

Refeyn’s SamuxMP enables routine quantification of empty/full AAV capsid ratios, even in smaller labs, to set a new standard in AAV characterization

Announced in January 2022, Refeyn’s SamuxMP mass photometer is designed to be used with only basic training. Intended for use in adeno-associated virus (AAV) analytics, it has a mass range tailored for AAV analysis and provides accurate results in less than five minutes from sample loading to final result. Combined with low-operational costs and a small footprint, the SamuxMP enables routine quantification of empty/full AAV capsid ratios, even in smaller labs, to set a new standard in AAV characterisation.

According to a company press release, the SamuxMP is designed to overcome the drawbacks of the current analytical methods by enabling users to rapidly and cost-effectively determine empty/full capsid ratios for AAVs of any serotype at the bench using very low sample volumes and concentrations with minimal sample preparation. This is intended to enhance productivity and speed up workflows through more frequent analyses in-house, making R&D and process development of gene therapies and AAV-based therapeutics significantly more efficient.

“We are delighted to announce the launch of our SamuxMP mass photometer for fast, accurate, and accessible AAV analysis”, said Anthony Fernandez, CEO, Refeyn, in the press release. “Mass photometry provides an opportunity to overcome the analytical bottleneck in the gene therapy sphere for AAV-based therapeutics and we wanted to develop an instrument that would enable a real gain in efficiency. The SamuxMP delivers precise results from the bench whilst reducing cost and preparation time. It will enable researchers to focus on what they do best, and make AAV analytics just another part of their day-to-day workflows. We look forward to working with the bioscience research community to continue delivering innovative instruments that will simplify biomolecule characterisation.”

Source: Refeyn